Cytokeratin 17 Mouse, Clone: KRT17/778, Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody

Catalog Number	Mfr. No.	Quantity
NBP247684A	Novus Biologicals NBP2476840.1MG	0.1 mg
NBP247684B	Novus Biologicals NBP2476840.2MG	0.2 mg

Description

Cytokeratin 17 Monoclonal specifically detects Cytokeratin 17 in Human, Rat, Porcine, Bovine, Goat samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.

Specifications

• Antigen: Cytokeratin 17
• Concentration: 1.0 mg/mL
• Applications: Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence, CyTOF
• Conjugate: Unconjugated
• Host Species: Mouse
• Research Discipline: Cancer
• Formulation: PBS with No Preservative
• Gene ID (Entrez): 3872
• Immunogen: Recombinant full-length human KRT17 protein
• Primary or Secondary: Primary
• Content And Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Molecular Weight of Antigen: 46 kDa

• Clone: KRT17/778
• Dilution: Flow Cytometry : 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin : 0.5 - 1.0 ug/ml, Immunofluorescence : 1 - 2 ug/ml, CyTOF-ready
• Classification: Monoclonal
• Form: Purified
• Regulatory Status: RUO
• Target Species: Human, Rat, Porcine, Goat, Primate
• Gene Alias: 39.1, CK-17, cytokeratin-17, K17, keratin 17, keratin, type I cytoskeletal 17, keratin-17, PC, PC2, PCHC1
• Gene Symbols: KRT17
• Isotype: IgG2b κ
• Purification Method: Protein A or G purified
• Test Specificity: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.